Functions and regulation of T cell-derived interleukin-10

Seminars in Immunology

Volumn 44, Issue , 2019, Pages

  Neumann, Christian ^a   Scheffold, Alexander ^b   Rutz, Sascha ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c GENENTECH INC   (United States)

Author keywords

Allergy; Autoimmune disease; Blimp 1; c Maf; GWAS; Human; IL 10; Infection; Inflammatory bowel disease; Intestinal homeostasis; Regulatory T cell; T cell; Transcriptional regulation; Tumor

Indexed keywords

ALPHA INTERFERON; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD45RB ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MEMBRANE COFACTOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; PROTEIN C JUN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; GENE EXPRESSION; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TH17 CELL; TRANSCRIPTION REGULATION; ULCERATIVE COLITIS; ANIMAL; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; INTESTINE;

ANIMALS; HOMEOSTASIS; HUMANS; INFECTIONS; INTERLEUKIN-10; INTESTINES; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 85075193333     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2019.101344     Document Type: Review

References (268)

1. Engelhardt, K.R., Grimbacher, B., IL-10 in humans: lessons from the gut, IL-10/IL-10 receptor deficiencies, and IL-10 polymorphisms. Curr. Top. Microbiol. Immunol. 380 (2014), 1–18.
2. Gabrysova, L., et al. The regulation of IL-10 expression. Curr. Top. Microbiol. Immunol. 380 (2014), 157–190.
3. Moore, K.W., et al. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001), 683–765.
4. O'Garra, A., et al. Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 223 (2008), 114–131.
5. Ouyang, W., et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29 (2011), 71–109.
6. Saraiva, M., O'Garra, A., The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10:3 (2010), 170–181.
7. Wang, X., et al. Targeting IL-10 family cytokines for the treatment of human diseases. Cold Spring Harb. Perspect. Biol., 11(2), 2019.
8. Kuhn, R., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:2 (1993), 263–274.
9. Couper, K.N., Blount, D.G., Riley, E.M., IL-10: the master regulator of immunity to infection. J. Immunol. 180:9 (2008), 5771–5777.
10. Redford, P.S., Murray, P.J., O'Garra, A., The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol. 4:3 (2011), 261–270.
11. Josephson, K., Logsdon, N.J., Walter, M.R., Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity 15:1 (2001), 35–46.
12. Zdanov, A., Structural analysis of cytokines comprising the IL-10 family. Cytokine Growth Factor Rev. 21:5 (2010), 325–330.
13. Ho, A.S., et al. A receptor for interleukin 10 is related to interferon receptors. Proc. Natl. Acad. Sci. U. S. A. 90:23 (1993), 11267–11271.
14. Kotenko, S.V., et al. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J. 16:19 (1997), 5894–5903.
15. Tan, J.C., et al. Characterization of interleukin-10 receptors on human and mouse cells. J. Biol. Chem. 268:28 (1993), 21053–21059.
16. Yoon, S.I., et al. Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. J. Biol. Chem. 281:46 (2006), 35088–35096.
17. Yoon, S.I., et al. Structure and mechanism of receptor sharing by the IL-10R2 common chain. Structure 18:5 (2010), 638–648.
18. Ho, A.S., et al. Functional regions of the mouse interleukin-10 receptor cytoplasmic domain. Mol. Cell. Biol. 15:9 (1995), 5043–5053.
19. Finbloom, D.S., Winestock, K.D., IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J. Immunol. 155:3 (1995), 1079–1090.
20. Meraz, M.A., et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:3 (1996), 431–442.
21. Takeda, K., et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:1 (1999), 39–49.
22. Shaw, M.H., et al. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. J. Immunol. 176:12 (2006), 7263–7271.
23. Rutz, S., Wang, X., Ouyang, W., The IL-20 subfamily of cytokines--from host defence to tissue homeostasis. Nat. Rev. Immunol. 14:12 (2014), 783–795.
24. Fiorentino, D.F., Bond, M.W., Mosmann, T.R., Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:6 (1989), 2081–2095.
25. de Waal Malefyt, R., et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:5 (1991), 1209–1220.
26. Creery, W.D., et al. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur. J. Immunol. 26:6 (1996), 1273–1277.
27. de Waal Malefyt, R., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174:4 (1991), 915–924.
28. Willems, F., et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 24:4 (1994), 1007–1009.
29. Schuetze, N., et al. IL-12 family members: differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages. Int. Immunol. 17:5 (2005), 649–659.
30. D'Andrea, A., et al. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J. Exp. Med. 181:2 (1995), 537–546.
31. Kamanaka, M., et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J. Exp. Med. 208:5 (2011), 1027–1040.
32. Huber, S., et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 34:4 (2011), 554–565.
33. Coomes, S.M., et al. CD4(+) Th2 cells are directly regulated by IL-10 during allergic airway inflammation. Mucosal Immunol. 10:1 (2017), 150–161.
34. Chen, W.F., Zlotnik, A., IL-10: a novel cytotoxic T cell differentiation factor. J. Immunol. 147:2 (1991), 528–534.
35. Rousset, F., et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 89:5 (1992), 1890–1893.
36. Chaudhry, A., et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34:4 (2011), 566–578.
37. Murai, M., et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat. Immunol. 10:11 (2009), 1178–1184.
38. Brockmann, L., et al. Molecular and functional heterogeneity of IL-10-producing CD4(+) T cells. Nat. Commun., 9(1), 2018, 5457.
39. Rutz, S., Ouyang, W., Regulation of Interleukin-10 expression. Adv. Exp. Med. Biol. 941 (2016), 89–116.
40. Spencer, S.D., et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J. Exp. Med. 187:4 (1998), 571–578.
41. Sellon, R.K., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 66:11 (1998), 5224–5231.
42. Madsen, K.L., et al. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 118:6 (2000), 1094–1105.
43. Franke, A., et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40:11 (2008), 1319–1323.
44. Sanchez, R., et al. IL-10 and TNF-alpha promoter haplotypes are associated with childhood Crohn's disease location. World J. Gastroenterol. 15:30 (2009), 3776–3782.
45. Franke, A., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42:12 (2010), 1118–1125.
46. Moran, C.J., et al. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm. Bowel Dis. 19:1 (2013), 115–123.
47. Glocker, E.O., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361:21 (2009), 2033–2045.
48. Begue, B., et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am. J. Gastroenterol. 106:8 (2011), 1544–1555.
49. Mao, H., et al. Exome sequencing identifies novel compound heterozygous mutations of IL-10 receptor 1 in neonatal-onset Crohn's disease. Genes Immun. 13:5 (2012), 437–442.
50. Kotlarz, D., et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 143:2 (2012), 347–355.
51. Shim, J.O., et al. Interleukin-10 receptor mutations in children with neonatal-onset Crohn's disease and intractable ulcerating enterocolitis. Eur. J. Gastroenterol. Hepatol. 25:10 (2013), 1235–1240.
52. Galatola, M., et al. Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis. World J. Gastroenterol. 19:46 (2013), 8659–8670.
53. Murugan, D., et al. Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. J. Clin. Immunol. 34:3 (2014), 331–339.
54. Kole, A., Maloy, K.J., Control of intestinal inflammation by interleukin-10. Curr. Top. Microbiol. Immunol. 380 (2014), 19–38.
55. Madan, R., et al. Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. J. Immunol. 183:4 (2009), 2312–2320.
56. Siewe, L., et al. Interleukin-10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA. Eur. J. Immunol. 36:12 (2006), 3248–3255.
57. Zigmond, E., et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 40:5 (2014), 720–733.
58. Roers, A., et al. T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J. Exp. Med. 200:10 (2004), 1289–1297.
59. Rubtsov, Y.P., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28:4 (2008), 546–558.
60. Neumann, C., et al. c-Maf-dependent Treg cell control of intestinal TH17 cells and IgA establishes host-microbiota homeostasis. Nat. Immunol. 20:4 (2019), 471–481.
61. Powrie, F., et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5:11 (1993), 1461–1471.
62. Asseman, C., et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190:7 (1999), 995–1004.
63. Maloy, K.J., Kullberg, M.C., IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunol. 1:5 (2008), 339–349.
64. Zhou, L., Sonnenberg, G.F., Essential immunologic orchestrators of intestinal homeostasis. Sci. Immunol., 3(20), 2018.
65. Esplugues, E., et al. Control of TH17 cells occurs in the small intestine. Nature 475:7357 (2011), 514–518.
66. Gagliani, N., et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523:7559 (2015), 221–225.
67. Brockmann, L., et al. IL-10 receptor signaling is essential for TR1 cell function in vivo. J. Immunol. 198:3 (2017), 1130–1141.
68. Chaudhry, A., et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326:5955 (2009), 986–991.
69. Panea, C., et al. Intestinal monocyte-derived macrophages control commensal-specific Th17 responses. Cell Rep. 12:8 (2015), 1314–1324.
70. Gutzeit, C., Magri, G., Cerutti, A., Intestinal IgA production and its role in host-microbe interaction. Immunol. Rev. 260:1 (2014), 76–85.
71. Kawamoto, S., et al. Foxp3(+) T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis. Immunity 41:1 (2014), 152–165.
72. Defrance, T., et al. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J. Exp. Med. 175:3 (1992), 671–682.
73. Kunisawa, J., et al. Microbe-dependent CD11b+ IgA+ plasma cells mediate robust early-phase intestinal IgA responses in mice. Nat. Commun., 4, 2013, 1772.
74. Linterman, M.A., et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat. Med. 17:8 (2011), 975–982.
75. Chung, Y., et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat. Med. 17:8 (2011), 983–988.
76. Peterson, L.W., Artis, D., Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14:3 (2014), 141–153.
77. Biton, M., et al. T helper cell cytokines modulate intestinal stem cell renewal and differentiation. Cell, 175(5), 2018 1307-1320 e22.
78. Goto, Y., et al. IL-10-producing CD4(+) T cells negatively regulate fucosylation of epithelial cells in the gut. Sci. Rep., 5, 2015, 15918.
79. Goto, Y., Uematsu, S., Kiyono, H., Epithelial glycosylation in gut homeostasis and inflammation. Nat. Immunol. 17:11 (2016), 1244–1251.
80. Shkoda, A., et al. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology 132:1 (2007), 190–207.
81. Hasnain, S.Z., et al. IL-10 promotes production of intestinal mucus by suppressing protein misfolding and endoplasmic reticulum stress in goblet cells. Gastroenterology, 144(2), 2013 357-368 e9.
82. Bharhani, M.S., et al. IL-10 protects mouse intestinal epithelial cells from Fas-induced apoptosis via modulating Fas expression and altering caspase-8 and FLIP expression. Am. J. Physiol. Gastrointest. Liver Physiol. 291:5 (2006), G820–9.
83. Denning, T.L., et al. Expression of IL-10 receptors on epithelial cells from the murine small and large intestine. Int. Immunol. 12:2 (2000), 133–139.
84. Bourreille, A., et al. Lack of interleukin 10 regulation of antigen presentation-associated molecules expressed on colonic epithelial cells. Eur. J. Clin. Invest. 29:1 (1999), 48–55.
85. Lanis, J.M., et al. Tryptophan metabolite activation of the aryl hydrocarbon receptor regulates IL-10 receptor expression on intestinal epithelia. Mucosal Immunol. 10:5 (2017), 1133–1144.
86. Kominsky, D.J., et al. IFN-gamma-mediated induction of an apical IL-10 receptor on polarized intestinal epithelia. J. Immunol. 192:3 (2014), 1267–1276.
87. Rutz, S., Eidenschenk, C., Ouyang, W., IL-22, not simply a Th17 cytokine. Immunol. Rev. 252:1 (2013), 116–132.
88. Bernshtein, B., et al. IL-23-producing IL-10Ralpha-deficient gut macrophages elicit an IL-22-driven proinflammatory epithelial cell response. Sci. Immunol., 4(36), 2019.
89. O'Garra, A., Vieira, P., T(H)1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7:6 (2007), 425–428.
90. Brooks, D.G., et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12:11 (2006), 1301–1309.
91. Ejrnaes, M., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 203:11 (2006), 2461–2472.
92. Brooks, D.G., et al. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 205:3 (2008), 533–541.
93. Moore, K.W., et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248:4960 (1990), 1230–1234.
94. Newton, S.M., et al. A deletion defining a common Asian lineage of Mycobacterium tuberculosis associates with immune subversion. Proc. Natl. Acad. Sci. U. S. A. 103:42 (2006), 15594–15598.
95. Ng, C.T., Oldstone, M.B., Infected CD8alpha- dendritic cells are the predominant source of IL-10 during establishment of persistent viral infection. Proc. Natl. Acad. Sci. U. S. A. 109:35 (2012), 14116–14121.
96. Anderson, C.F., et al. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204:2 (2007), 285–297.
97. Belkaid, Y., et al. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:6915 (2002), 502–507.
98. Couper, K.N., et al. IL-10 from CD4CD25Foxp3CD127 adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PLoS Pathog., 4(2), 2008, e1000004.
99. Jankovic, D., et al. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204:2 (2007), 273–283.
100. Moreira-Teixeira, L., et al. T cell-derived IL-10 impairs host resistance to Mycobacterium tuberculosis infection. J. Immunol. 199:2 (2017), 613–623.
101. Eidenschenk, C., et al. Role of IL-22 in microbial host defense. Curr. Top. Microbiol. Immunol. 380 (2014), 213–236.
102. Freitas do Rosario, A.P., et al. IL-27 promotes IL-10 production by effector Th1 CD4+ T cells: a critical mechanism for protection from severe immunopathology during malaria infection. J. Immunol. 188:3 (2012), 1178–1190.
103. Redford, P.S., et al. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur. J. Immunol. 40:8 (2010), 2200–2210.
104. Huynh, J.P., et al. Bhlhe40 is an essential repressor of IL-10 during Mycobacterium tuberculosis infection. J. Exp. Med. 215:7 (2018), 1823–1838.
105. Turner, J., et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J. Immunol. 169:11 (2002), 6343–6351.
106. van Tong, H., et al. Human genetic factors in tuberculosis: an update. Trop. Med. Int. Health 22:9 (2017), 1063–1071.
107. Meyer, C.G., Thye, T., Host genetic studies in adult pulmonary tuberculosis. Semin. Immunol. 26:6 (2014), 445–453.
108. Saraiva, M., et al. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31:2 (2009), 209–219.
109. Meyaard, L., et al. IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J. Immunol. 156:8 (1996), 2776–2782.
110. Gerosa, F., et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J. Exp. Med. 183:6 (1996), 2559–2569.
111. Shoemaker, J., Saraiva, M., O'Garra, A., GATA-3 directly remodels the IL-10 locus independently of IL-4 in CD4+ T cells. J. Immunol. 176:6 (2006), 3470–3479.
112. Chang, H.D., et al. Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. Eur. J. Immunol. 37:3 (2007), 807–817.
113. Stumhofer, J.S., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8:12 (2007), 1363–1371.
114. Xu, J., et al. c-Maf regulates IL-10 expression during Th17 polarization. J. Immunol. 182:10 (2009), 6226–6236.
115. Kastelein, R.A., Hunter, C.A., Cua, D.J., Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25 (2007), 221–242.
116. Hunter, C.A., Kastelein, R., Interleukin-27: balancing protective and pathological immunity. Immunity 37:6 (2012), 960–969.
117. Villarino, A., et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19:5 (2003), 645–655.
118. Stumhofer, J.S., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7:9 (2006), 937–945.
119. Rutz, S., et al. Notch regulates IL-10 production by T helper 1 cells. Proc. Natl. Acad. Sci. U. S. A. 105:9 (2008), 3497–3502.
120. Kassner, N., et al. Cutting edge: plasmacytoid dendritic cells induce IL-10 production in T cells via the delta-like-4/Notch axis. J. Immunol. 184:2 (2010), 550–554.
121. McNab, F.W., et al. Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-gamma for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages. J. Immunol. 193:7 (2014), 3600–3612.
122. Oldstone, M.B., A Jekyll and Hyde profile: type 1 Interferon signaling plays a prominent role in the initiation and maintenance of a persistent virus infection. J. Infect. Dis. 212:Suppl. 1 (2015), S31–6.
123. Teijaro, J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340:6129 (2013), 207–211.
124. Wilson, E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340:6129 (2013), 202–207.
125. Roncarolo, M.G., et al. The biology of t regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity 49:6 (2018), 1004–1019.
126. Naing, A., et al. Safety, antitumor activity, and immune activation of pegylated recombinant human Interleukin-10 (AM0010) in patients with advanced solid tumors. J. Clin. Oncol. 34:29 (2016), 3562–3569.
127. Naing, A., et al. PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8(+) T cell invigoration and polyclonal t cell expansion in cancer patients. Cancer Cell, 34(5), 2018 775-791 e3.
128. Groux, H., et al. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J. Immunol. 160:7 (1998), 3188–3193.
129. Mumm, J.B., et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 20:6 (2011), 781–796.
130. Emmerich, J., et al. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 72:14 (2012), 3570–3581.
131. Bacher, P., Scheffold, A., The effect of regulatory T cells on tolerance to airborne allergens and allergen immunotherapy. J. Allergy Clin. Immunol. 142:6 (2018), 1697–1709.
132. Ozcan, E., Notarangelo, L.D., Geha, R.S., Primary immune deficiencies with aberrant IgE production. J. Allergy Clin. Immunol. 122:6 (2008), 1054–1062 quiz 1063-4.
133. Georgiev, P., Charbonnier, L.M., Chatila, T.A., Regulatory t cells: the many faces of Foxp3. J. Clin. Immunol. 39:7 (2019), 623–640.
134. McGovern, D.P., Kugathasan, S., Cho, J.H., Genetics of inflammatory bowel diseases. Gastroenterology, 149(5), 2015 1163-1176 e2.
135. Ellinghaus, D., et al. Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology 145:2 (2013), 339–347.
136. Schmiedel, B.J., et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell, 175(6), 2018 1701-1715 e16.
137. Grimbacher, B., et al. The crossroads of autoimmunity and immunodeficiency: lessons from polygenic traits and monogenic defects. J. Allergy Clin. Immunol. 137:1 (2016), 3–17.
138. International Multiple Sclerosis Genetics, C, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45:11 (2013), 1353–1360.
139. Ramakrishnan, V., Akram Husain, R.S., Ahmed, S.S., Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: a meta-analysis. J. Neuroimmunol. 306 (2017), 11–18.
140. Okada, Y., et al. Genetics of rheumatoid arthritis: 2018 status. Ann. Rheum. Dis. 78:4 (2019), 446–453.
141. Moffatt, M.F., et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363:13 (2010), 1211–1221.
142. Zhu, Z., et al. A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases. Nat. Genet. 50:6 (2018), 857–864.
143. Barrett, J.C., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41:6 (2009), 703–707.
144. Ellinghaus, D., et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat. Genet. 48:5 (2016), 510–518.
145. Wahren-Herlenius, M., Dorner, T., Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382:9894 (2013), 819–831.
146. Gateva, V., et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41:11 (2009), 1228–1233.
147. Ye, C.J., et al. Intersection of population variation and autoimmunity genetics in human T cell activation. Science, 345(6202), 2014, 1254665.
148. Bacher, P., Scheffold, A., New technologies for monitoring human antigen-specific T cells and regulatory T cells by flow-cytometry. Curr. Opin. Pharmacol. 23 (2015), 17–24.
149. Herold, K.C., et al. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat. Rev. Immunol. 13:4 (2013), 243–256.
150. Dendrou, C.A., Fugger, L., Friese, M.A., Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15:9 (2015), 545–558.
151. Belkaid, Y., Harrison, O.J., Homeostatic immunity and the microbiota. Immunity 46:4 (2017), 562–576.
152. Bacher, P., Scheffold, A., Antigen-specific regulatory T-cell responses against aeroantigens and their role in allergy. Mucosal Immunol. 11:6 (2018), 1537–1550.
153. Valenta, R., et al. Molecular aspects of allergens and allergy. Adv. Immunol. 138 (2018), 195–256.
154. Meiler, F., et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med. 205:12 (2008), 2887–2898.
155. Akdis, M., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. 199:11 (2004), 1567–1575.
156. Shamji, M.H., Durham, S.R., Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J. Allergy Clin. Immunol. 140:6 (2017), 1485–1498.
157. Bacher, P., et al. Regulatory T cell specificity directs tolerance versus allergy against aeroantigens in humans. Cell, 167(4), 2016 1067-1078 e16.
158. Jones, E.A., Flavell, R.A., Distal enhancer elements transcribe intergenic RNA in the IL-10 family gene cluster. J. Immunol. 175:11 (2005), 7437–7446.
159. Wang, Z.Y., et al. Regulation of IL-10 gene expression in Th2 cells by Jun proteins. J. Immunol. 174:4 (2005), 2098–2105.
160. Im, S.H., et al. Chromatin-level regulation of the IL10 gene in T cells. J. Biol. Chem. 279:45 (2004), 46818–46825.
161. Trandem, K., et al. Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis. J. Immunol. 186:6 (2011), 3642–3652.
162. Ciofani, M., et al. A validated regulatory network for Th17 cell specification. Cell 151:2 (2012), 289–303.
163. Tussiwand, R., et al. Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 490:7421 (2012), 502–507.
164. Glasmacher, E., et al. A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science 338:6109 (2012), 975–980.
165. Li, P., et al. BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature 490:7421 (2012), 543–546.
166. Murphy, T.L., Tussiwand, R., Murphy, K.M., Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat. Rev. Immunol. 13:7 (2013), 499–509.
167. Ahyi, A.N., et al. IFN regulatory factor 4 regulates the expression of a subset of Th2 cytokines. J. Immunol. 183:3 (2009), 1598–1606.
168. Macian, F., NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5:6 (2005), 472–484.
169. Lee, C.G., et al. A distal cis-regulatory element, CNS-9, controls NFAT1 and IRF4-mediated IL-10 gene activation in T helper cells. Mol. Immunol. 46:4 (2009), 613–621.
170. Ziegler-Heitbrock, L., et al. IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J. Immunol. 171:1 (2003), 285–290.
171. Unterberger, C., et al. Role of STAT3 in glucocorticoid-induced expression of the human IL-10 gene. Mol. Immunol. 45:11 (2008), 3230–3237.
172. Neumann, C., et al. Role of Blimp-1 in programing Th effector cells into IL-10 producers. J. Exp. Med. 211:9 (2014), 1807–1819.
173. Wei, L., et al. Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. Immunity 32:6 (2010), 840–851.
174. Fitzgerald, D.C., et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8:12 (2007), 1372–1379.
175. Batten, M., et al. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J. Immunol. 180:5 (2008), 2752–2756.
176. Awasthi, A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8:12 (2007), 1380–1389.
177. Pot, C., et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 183:2 (2009), 797–801.
178. Spolski, R., et al. IL-21 mediates suppressive effects via its induction of IL-10. J. Immunol. 182:5 (2009), 2859–2867.
179. Ansari, N.A., et al. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J. Immunol. 186:7 (2011), 3977–3985.
180. Kastirr, I., et al. IL-21 is a central memory T cell-associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells. J. Immunol. 193:7 (2014), 3322–3331.
181. Ghoreschi, K., et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467:7318 (2010), 967–971.
182. Kitani, A., et al. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J. Exp. Med. 198:8 (2003), 1179–1188.
183. Huss, D.J., et al. TGF-beta signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAE. Eur. J. Immunol. 41:10 (2011), 2987–2996.
184. Blokzijl, A., ten Dijke, P., Ibanez, C.F., Physical and functional interaction between GATA-3 and Smad3 allows TGF-beta regulation of GATA target genes. Curr. Biol. 12:1 (2002), 35–45.
185. Veldhoen, M., et al. Transforming growth factor-beta’ reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9:12 (2008), 1341–1346.
186. Dardalhon, V., et al. IL-4 inhibits TGF-beta-induced Foxp3+ t cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector t cells. Nat. Immunol. 9:12 (2008), 1347–1355.
187. Evans, H.G., et al. TNF-alpha blockade induces IL-10 expression in human CD4+ T cells. Nat. Commun., 5, 2014, 3199.
188. Roberts, C.A., et al. TNF blockade maintains an IL-10(+) phenotype in human effector CD4(+) and CD8(+) t cells. Front. Immunol., 8, 2017, 157.
189. Vahedi, G., et al. STATs shape the active enhancer landscape of T cell populations. Cell 151:5 (2012), 981–993.
190. Zhu, J., et al. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat. Immunol. 5:11 (2004), 1157–1165.
191. Kim, J.I., et al. The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines. Immunity 10:6 (1999), 745–751.
192. Schulz, E.G., et al. Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. Immunity 30:5 (2009), 673–683.
193. Sun, M., et al. RORgammat represses IL-10 production in Th17 cells to maintain their pathogenicity in inducing intestinal inflammation. J. Immunol. 202:1 (2019), 79–92.
194. Bauquet, A.T., et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat. Immunol. 10:2 (2009), 167–175.
195. Apetoh, L., et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 11:9 (2010), 854–861.
196. Gabrysova, L., et al. c-Maf controls immune responses by regulating disease-specific gene networks and repressing IL-2 in CD4(+) T cells. Nat. Immunol. 19:5 (2018), 497–507.
197. Xu, M., et al. c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature 554:7692 (2018), 373–377.
198. Rutz, S., et al. Transcription factor c-Maf mediates the TGF-beta-dependent suppression of IL-22 production in T(H)17 cells. Nat. Immunol. 12:12 (2011), 1238–1245.
199. Aschenbrenner, D., et al. An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells. Nat. Immunol. 19:10 (2018), 1126–1136.
200. Perucha, E., et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nat. Commun., 10(1), 2019, 498.
201. Gandhi, R., et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat. Immunol. 11:9 (2010), 846–853.
202. Quintana, F.J., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453:7191 (2008), 65–71.
203. Veldhoen, M., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453:7191 (2008), 106–109.
204. Tousa, S., et al. Activin-A co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses. Proc. Natl. Acad. Sci. U. S. A. 114:14 (2017), E2891–E2900.
205. Yu, F., et al. The transcription factor Bhlhe40 is a switch of inflammatory versus antiinflammatory Th1 cell fate determination. J. Exp. Med. 215:7 (2018), 1813–1821.
206. Lin, C.C., et al. IL-1-induced Bhlhe40 identifies pathogenic T helper cells in a model of autoimmune neuroinflammation. J. Exp. Med. 213:2 (2016), 251–271.
207. Gabrysova, L., O'Garra, A., Regulating the regulator: Bhlhe40 directly keeps IL-10 in check. J. Exp. Med. 215:7 (2018), 1767–1769.
208. Kallies, A., et al. Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance. Nat. Immunol. 7:5 (2006), 466–474.
209. Martins, G.A., et al. Transcriptional repressor Blimp-1 regulates T cell homeostasis and function. Nat. Immunol. 7:5 (2006), 457–465.
210. Sun, J., et al. CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat. Immunol. 12:4 (2011), 327–334.
211. Iwasaki, Y., et al. Egr-2 transcription factor is required for Blimp-1-mediated IL-10 production in IL-27-stimulated CD4+ T cells. Eur. J. Immunol. 43:4 (2013), 1063–1073.
212. Cretney, E., et al. The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat. Immunol. 12:4 (2011), 304–311.
213. Parish, I.A., et al. Chronic viral infection promotes sustained Th1-derived immunoregulatory IL-10 via BLIMP-1. J. Clin. Invest. 124:8 (2014), 3455–3468.
214. Martins, G., Calame, K., Regulation and functions of Blimp-1 in t and B lymphocytes. Annu. Rev. Immunol. 26 (2008), 133–169.
215. Zhang, P., et al. Eomesodermin promotes the development of type 1 regulatory T (TR1) cells. Sci. Immunol., 2(10), 2017.
216. Gruarin, P., et al. Eomesodermin controls a unique differentiation program in human IL-10 and IFN-gamma coproducing regulatory T cells. Eur. J. Immunol. 49:1 (2019), 96–111.
217. Aman, M.J., et al. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood 87:11 (1996), 4731–4736.
218. Corre, B., et al. Type I interferon potentiates T-cell receptor mediated induction of IL-10-producing CD4(+) T cells. Eur. J. Immunol. 43:10 (2013), 2730–2740.
219. Levings, M.K., et al. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166:9 (2001), 5530–5539.
220. Hinks, A., et al. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat. Genet. 45:6 (2013), 664–669.
221. Langefeld, C.D., et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat. Commun., 8, 2017, 16021.
222. Jakkula, E., et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am. J. Hum. Genet. 86:2 (2010), 285–291.
223. Patsopoulos, N.A., et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann. Neurol. 70:6 (2011), 897–912.
224. International Multiple Sclerosis Genetics, C, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:7359 (2011), 214–219.
225. Barrett, J.C., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40:8 (2008), 955–962.
226. Denny, J.C., et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat. Biotechnol. 31:12 (2013), 1102–1110.
227. Paternoster, L., et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat. Genet. 47:12 (2015), 1449–1456.
228. de la Rosa, M., et al. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 34:9 (2004), 2480–2488.
229. Barthlott, T., et al. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int. Immunol. 17:3 (2005), 279–288.
230. Ferreira, M.A., et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nat. Genet. 49:12 (2017), 1752–1757.
231. Pividori, M., et al. Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies. Lancet Respir. Med. 7:6 (2019), 509–522.
232. Ferreira, M.A.R., et al. Genetic architectures of childhood- and adult-onset asthma are partly distinct. Am. J. Hum. Genet. 104:4 (2019), 665–684.
233. Fishman, D., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102:7 (1998), 1369–1376.
234. Eyre, S., et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 44:12 (2012), 1336–1340.
235. Groux, H., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:6652 (1997), 737–742.
236. Liu, J.Z., et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47:9 (2015), 979–986.
237. Consortium, U.I.G., et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat. Genet. 41:12 (2009), 1330–1334.
238. Franke, A., et al. Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat. Genet. 42:4 (2010), 292–294.
239. Bentham, J., et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 47:12 (2015), 1457–1464.
240. de Lange, K.M., et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49:2 (2017), 256–261.
241. Huang, C., et al. Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology 149:6 (2015), 1575–1586.
242. Li, Y.R., et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat. Med. 21:9 (2015), 1018–1027.
243. Acosta-Herrera, M., et al. Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. Ann. Rheum. Dis. 78:3 (2019), 311–319.
244. De Jager, P.L., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41:7 (2009), 776–782.
245. Chung, S.A., et al. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet., 7(3), 2011, e1001323.
246. Morris, D.L., et al. Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. Nat. Genet. 48:8 (2016), 940–946.
247. Hinds, D.A., et al. A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci. Nat. Genet. 45:8 (2013), 907–911.
248. Murugaiyan, G., et al. IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J. Immunol. 183:4 (2009), 2435–2443.
249. Kakuta, Y., et al. A genome-wide association study identifying RAP1A as a novel susceptibility gene for Crohn's disease in Japanese individuals. J. Crohns Colitis 13:5 (2019), 648–658.
250. Pickrell, J.K., et al. Detection and interpretation of shared genetic influences on 42 human traits. Nat. Genet. 48:7 (2016), 709–717.
251. Waage, J., et al. Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. Nat. Genet. 50:8 (2018), 1072–1080.
252. Stahl, E.A., et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42:6 (2010), 508–514.
253. Kemper, C., et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421:6921 (2003), 388–392.
254. Cardone, J., et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat. Immunol. 11:9 (2010), 862–871.
255. Jostins, L., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:7422 (2012), 119–124.
256. Anderson, C.A., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 43:3 (2011), 246–252.
257. Okamura, T., et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc. Natl. Acad. Sci. U. S. A. 106:33 (2009), 13974–13979.
258. Cutler, D.J., et al. Dissecting allele architecture of early onset IBD using high-density genotyping. PLoS One, 10(6), 2015, e0128074.
259. Okada, Y., et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506:7488 (2014), 376–381.
260. Laufer, V.A., et al. Genetic influences on susceptibility to rheumatoid arthritis in African-Americans. Hum. Mol. Genet. 28:5 (2019), 858–874.
261. Koh, B., et al. Etv5 regulates IL-10 production in Th cells. J. Immunol. 198:5 (2017), 2165–2171.
262. Motomura, Y., et al. The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells. Nat. Immunol. 12:5 (2011), 450–459.
263. Kim, K., et al. High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. Ann. Rheum. Dis., 74(3), 2015, e13.
264. Lee, C.G., et al. IRF4 regulates IL-10 gene expression in CD4(+) T cells through differential nuclear translocation. Cell. Immunol. 268:2 (2011), 97–104.
265. Kichaev, G., et al. Leveraging polygenic functional enrichment to improve GWAS power. Am. J. Hum. Genet. 104:1 (2019), 65–75.
266. Grenningloh, R., Kang, B.Y., Ho, I.C., Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses. J. Exp. Med. 201:4 (2005), 615–626.
267. Lee, C.G., et al. Interaction of Ets-1 with HDAC1 represses IL-10 expression in Th1 cells. J. Immunol. 188:5 (2012), 2244–2253.
268. Hill, E.V., et al. Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T-cell subsets through epigenetic modification of the IL-10 promoter. Eur. J. Immunol. 45:4 (2015), 1103–1115.